Ricardo Blanco - Concepedia

Author

Ricardo Blanco

Marqués de Valdecilla University Hospital ORCID

Also Known As

Alonso, R. B., Blanco R, Blanco, R, Blanco, R., Blanco, Ricardo, Christopher T. Ritchlin, G. González-Ortega, Irene Llorente, Isabel Almeida, José-Ezequiel Martin

1.1K

Publications

19.5K

Citations

H-Index

203

Concepts

All Affiliations

Marqués de Valdecilla University Hospital Universidad de Cantabria Instituto de Investigación Marqués de Valdecilla Hospital Universitario de La Princesa Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública

About

Ricardo Blanco is an author at Marqués de Valdecilla University Hospital specializing in medicine, rheumatology, and autoimmune disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	37	91	5K
2	Public Health	13	15	613
3	Health Sciences	12	14	402
4	Engineering	2	2	26
5	Natural Sciences	1	1	12

Ricardo Blanco

292

Publications

15.7K

Citations

H-Index

Page 1

	Year	Citations
Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial Gerd R Burmester, Ricardo Blanco, Christina Charles‐Schoeman, The Lancet InflammationRheumatologyRheumatoid DisorderAnti-inflammatoryMedicine	2013	714
Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors Dafna D. Gladman, William F. C. Rigby, Valderílio Feijó Azevedo, New England Journal of Medicine	2017	494
Henoch‐Schönlein purpura in adulthood and childhood. Two different expressions of the same syndrome Ricardo Blanco, Víctor M. Martínez‐Taboada, Vicente Rodríguez‐Valverde, Arthritis & Rheumatism	1997	417
Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structu Joel M. Kremer, Ricardo Blanco, Marek Brzosko, Arthritis & Rheumatism	2010	410
Permanent visual loss and cerebrovascular accidents in giant cell arteritis: Predictors and response to treatment Miguel Á. González‐Gay, Ricardo Blanco, Vicente Rodríguez‐Valverde, Arthritis & Rheumatism	1998	403
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial Peter Nash, Bruce Kirkham, Masato Okada, The Lancet Rheumatoid DisorderRheumatologySpirit-p2 Phase 3Autoimmune DiseaseMedicine	2017	390
Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis Andrew D. Dick, James T. Rosenbaum, Hassan Al-Dhibi, Ophthalmology	2018	244
Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study José L. Pablos, María Galindo-Izquierdo, Loreto Carmona, Annals of the Rheumatic Diseases	2020	235
Treatment of Refractory Uveitis with Adalimumab: A Prospective Multicenter Study of 131 Patients M. Díaz-Llopis, David Salom, Carmen García-De-Vicuña, Ophthalmology Refractory UveitisRheumatologyOcular DiseaseOphthalmologyProspective Multicenter Study	2012	230
Strokes at Time of Disease Diagnosis in a Series of 287 Patients With Biopsy-Proven Giant Cell Arteritis Miguel Á. González‐Gay, Tomás R. Vázquez-Rodríguez, Inés Gómez‐Acebo, Medicine	2009	230

Page 1